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Multiple familial trichoepithelioma (MFT) is an autosomal dominant skin disease characterized by the presence of
many small benign tumors with pilar differentiation predominantly on the face. The ﬁrst locus has been previously
mapped to chromosome 9p21, but no gene for MFT has been identiﬁed to date. To identify the disease gene in a
large Chinese family, we initially performed linkage analysis with microsatellite markers from 9p21, but failed to
conﬁrm the linkage to this region. Previous publications showed MFT and familial cylindromatosis (FC) can occur
within one family and in a single person. Therefore, we speculated that the cylindromatosis gene (CYLDI gene)
responsible for FC may be related to the pathogenesis of MFT. In view of that, we genotyped all available
individuals using 11 microsatellite markers spanning the CYLDI gene region at 16q12–q13. We identiﬁed the linkage
of MFT to this region. Mutation analysis in the CYLDI gene detected a frameshift mutation, designated as c.2355–
2358delCAGA. The study ﬁrstly identiﬁed the cylindromatosis gene responsible for MFT and showed that different
mutations of the CYLDI gene can give rise to distinct clinical and histological expression such as FC and MFT.
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Trichoepithelioma is a benign cutaneous tumor that origi-
nates from hair follicles. It occurs as a sporadic non-familial
and a multiple-familial type. The multiple familial tricho-
epithelioma (MFT) (OMIM number 601606) is a relatively
common genetic dermatosis characterized by the presence
of many skin-colored small tumors located predominantly not
only in the nasolabial folds but also on the nose, forehead,
upper lip, and occasionally on the scalp, neck, and upper
trunk, which is inherited in an autosomal dominant pattern.
Because the histological features are dermal aggregates of
basaloid cells with connection to or differentiation toward hair
follicles, this disorder has been thought to represent a benign
hamartoma of the pilosebaceous apparatus.
Harada et al (1996) have carried out linkage analysis in
three American MFT families and mapped the first locus for
MFT to a 4 cM region at 9p21 involved in the tumorigenesis.
Nevertheless, to date, no other research groups have
replicated the finding on chromosome 9p21. The sporadic
trichoepithelioma occurs more commonly than MFT and is
not inherited, and loss of heterozygosity studies demon-
strated deletions at 9q22.3 similar to that of sporadic basal
cell carcinoma (BCC) (Matt et al, 2000).
Familial cylindromatosis (FC) (OMIM number 132700) is
also a dominant predisposition to multiple neoplasms of the
skin appendages. The locus for FC on chromosome 16q12–
q13 was demonstrated (Biggs et al, 1995; Takahashi et al,
2000) and several groups were able to show loss of
heterozygosity at 16q in sporadic cylindromas as well as
FC (Biggs et al, 1995; Verhoef et al, 1998; Thomson et al,
1999; Leonard et al, 2001). Twenty germline mutations and
six somatic mutations have been detected in the cylindro-
matosis gene (CYLD1 gene) (Bignell et al, 2000; Poblete
Gutierrez et al, 2002). MFT and FC can occur within one
family and in a single person (Gerretsen et al, 1995), which
suggests that the two types of dermatosis may be caused
by dysfunction of the same gene. It may be that there are
two forms of MFT: one that occurs in isolation is determined
by a gene in the region at 9p mapped by Harada et al (1996),
and another that co-occurs with FC is determined by a gene
on chromosome 16.
The gene for MFT is unknown to date. To identify the
disease gene, we herein studied a three-generation Chinese
family with MFT. Linkage analysis using markers on chro-
mosome 9p21 excluded the linkage to this region in this
family, which suggested that MFT was a genetically
heterogeneous disorder. Then we focused our investigation
on 16q12–q13 and identified the locus for this family at this
region. By mutation analysis, we firstly found a frameshift
mutation of c.2355–2358delCAGA in the CYLD1 gene,
which was responsible for MFT.
Results
Clinical ﬁndings The proband (III-6) is a 9-y-old girl who
developed numerous tumors on her face from 5 y old. Most
of the lesions were dome-shaped, skin-colored, firm
Abbreviations: BCC, basal cell carcinoma; CYLD1 gene, cylindro-
matosis gene; FC, familial cylindromatosis; MFT, Multiple familial
trichoepithelioma
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papules between 5 and 8 mm in size. Other affected
individuals also developed the characteristic facial trichoe-
pitheliomas. The lesions increase steadily both in number
and size along with age. Subjective symptoms were limited
to occasional itching and psycho-social problems due to
disfigurement. The clinical features of this family were listed
in Table I. The mean age of onset was 12 y varying from 5
to 16 y. The lesions increased in number and size till
approximately 25 y of age, and then gradually regressed
along with age.
Skin specimen obtained from the nasolabial region of the
proband revealed the typical histopathological character-
istics of trichoepithelioma (Fig 1).
Two-point linkage analysis We initially analyzed seven
microsatellite markers from the previously mapped region at
9p21 and observed pairwise LOD scores of less than 2 for
each marker. As a result, the linkage to this region was
excluded for this family. To identify the locus for MFT in this
family, we analyzed the same set of genomic DNAs with
three microsatellite markers at 16q12–q13 (D16S3112,
D16S308, D16S3116). The presence of linkage to chromo-
some 16q was suggested by a two-point LOD score of 2.41
at D16S308 (y¼0.00). For fine mapping of this gene, a
further eight microsatellite markers from this region were
tested. Two-point LOD scores between the relevant
markers and the disease locus are shown in Table II. The max-
imum two-point LOD score was 3.31 (y¼ 0.00) for marker
D16S3044.
Haplotype analysis Haplotype was constructed with Cy-
rillic version 2.02 software to define the borders of the
critical region (Fig 2). The crossover in normal individual III-8
places the MFT locus distal to D16S3116. The distal border
of MFT is defined to D16S415 by a crossover event in
individual II-7. These results indicate that the gene
responsible for MFT lies in the 16 cM interval between
D16S3116 and D16S415.
Identiﬁcation of a causative mutation in the CYLD1
gene The CYLD1 gene falls within the identified locus at
16q12–q13 for MFT. By direct sequencing, we detected a
four-basepair deletion at nucleotide position 5–8 of exon 18
in the CYLD1 gene leading to a frameshift mutation (Fig 3) in
genomic DNAs of all seven patients, designated c.2355–
2358delCAGA corresponding to the cDNA sequence of the
gene beginning with A of the ATG translation start site
(Antonarakis et al, 1998). We did not find this frameshift
mutation in 12 normal individuals of this MFT family and 200
unrelated, population-matched control individuals.
Discussion
In this study, we identified a frameshift mutation in the
CYLD1 gene responsible for MFT in a Chinese family. For
the first time we were able to present evidence that MFTand
FC were allelic disorders caused by different mutations in
the same gene CYLD1 and demonstrated that MFT was a
genetically heterogeneous disorder on the molecular level.
Differentiation of MFT from FC is important because they
are associated with the same gene. Clinically, FC begins to
appear in the second or third decades predominantly in
Table I. Review of clinical ﬁndings in affected members of the family with MFT
ID no. Sex Age at examination Location Number Size (mm) Age of onset (y)
I–2 F 68 y AþBþCþD þ þ þ þ 5–20 14
II–2 M — AþBþC þ þ þ þ 5–15 16
II–5 M — AþB þ þ þ 5–20 11
II–7 M 35 y A þC þ þ 5–15 15
II–10 F 29 y AþBþCþD þ þ þ þ 5–20 13
III–1 F 17 y AþBþC þ þ þ 5–8 14
III–2 F 16 y AþBþC þ þ 5–10 10
III–6 F 9 y AþBþCþD þ þ þ þ 5–8 5
III–9 F 15 y AþBþC þ þ 5–10 10
Note: ID no, individual number in the pedigree; —, the individual died; A, nasolabial folds; B, nose; C, forehead; D, upper lip; þ , 1–5; þ þ , 5–10;
þ þ þ , 10–20; þ þ þ þ , 420.
Figure1
Histology of trichoepithelioma excised from the face of the
proband (hematoxylin and eosin staining). Well-demarcated nodules
consist of small basaloid cells that are arranged in a palisade-like
pattern; multiple horn cysts with a fully keratinized center surrounded
by basaloid cells lie free in the fibrous stroma.
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hairy areas of the body, accumulating in number and
increasing slowly in size throughout adult life (van Balkom
and Hennekam, 1994). The tumors sometimes lead to the
formation of a confluent mass that may ulcerate or become
infected. Malignant change with distant metastasis does
occur (Gerretsen et al, 1993; Sybert, 1997), but is unusual.
For MFT, it occurs in childhood or adolescence. The lesions
characteristically grow for a limited time and stabilize in size
within a few years. Some of the lesions show spontaneous
remission over the years and rare malignant changes occur.
Histologically, numerous isolated islands of epithelial cells
that are surrounded and separated from each other by PAS
positive staining material suggest the features of FC,
whereas primitive hair structures, cornified cysts, a palisade
pattern, and stromal fibrosis favor a diagnosis of MFT. The
clinical and histopathological findings in our patients are
fully consistent with MFT. MFT can usually be differentiated
from BCC because of its characteristic clinical presentation.
Histopathologic criteria for differentiation between BCC and
MFT are well estabished (Johnson et al, 1993). In addition,
the positive stain of CD34 in trichoepithelioma is a useful
distinguishing feature (Kirchmann et al, 1994). Genetically,
the gene for hereditary BCC has been assigned to chro-
mosome 9q22.3–q31 and mutations of the PTCH gene are
detected in hereditary BCC (Bale et al, 1994).
The CYLD1 gene is composed of 20 exons, of which the
first three are untranslated, and extends over approximately
56 kb genomic DNA. The full-length cDNA was predicted to
encode a protein of 956 amino acids. In 2000, Bignell and
colleagues reported the first mutations in the CYLD1 gene
causing FC. All the mutations are located in the 30 two-thirds
of the CYLD1 coding sequence. Loss of heterozygosity of
the wild-type allele of CYLD1 gene suggested that it is a
tumor-suppressor gene that follows the classic two-hit
model (Knudson, 1971). Recently, Poblete Gutierrez and
colleagues detected a frameshift mutation in the CYLD1
gene, designated 2253delG, and were able to show that a
single mutation can induce the co-occurrence of cylindro-
mas and trichoepitheliomas. The mutation study in our
isolated MFT family was further able to demonstrate that
MFT is allelic to FC. The location and type of each mutation
detected in the CYLD1 gene to date are depicted in Fig 4,
which did not reveal any clear phenotype–genotype
correlation. Therefore, the data mentioned above strongly
demonstrate that the CYLD1 gene characterizes pleiotropy
that mutations in the same gene can induce several different
phenotypes, and that different genes such as CYLD1 and a
hitherto unknown gene on 9p21 can respectively lead to the
same disorder MFT.
The CYLD1 protein is believed to be a cytoskeletal
protein containing four recognizable groups of sequence
motifs: three CAP-GLY domains, one proline-rich repeat,
two UCH (ubiquitin carboxy-terminal hydrolases) catalytic
domains, and four Cys-X-X-Cys pairs. The function of each
part has been demonstrated in previous data (Bignell et al,
2000). It contains three conserved domains, and the
Table II. Two-point LOD scores between the MFT locus and markers on chromosome 9p and 16q
Markers Location (cM)
LOD score at h¼
Zmax ymax0.00 0.10 0.20 0.30 0.40
D9S157 31.8 13.55 3.15 1.56 0.74 0.26 0.26 0.40
D9S162 33.3 4.11 0.81 0.31 0.09 0.00 0.00 0.40
D9S1870 36.5 14.43 3.14 1.56 0.74 0.26 0.26 0.40
D9S171 42 6.69 1.51 0.71 0.31 0.09 0.09 0.40
D9S1833 45 13.93 2.89 1.36 0.59 0.18 0.18 0.40
D9S169 48.2 10.82 2.21 0.97 0.38 0.09 0.09 0.40
D9S161 50.3 6.89 1.06 0.37 0.08 0.03 0.03 0.40
D16S3076 44.2 1.20 0.58 0.62 0.51 0.30 0.62 0.20
D16S3068 46.6 2.41 1.97 1.50 0.98 0.44 2.41 0.00
D16S3116 49.6 0.31 1.81 1.55 1.09 0.53 1.81 0.10
D16S3093 50.8 2.61 2.19 1.71 1.15 0.54 2.61 0.00
D16S409 56.2 2.10 1.78 1.43 1.02 0.55 2.10 0.00
D16S3044 56.7 3.31 2.76 2.15 1.46 0.70 3.31 0.00
D16S308 61.2 2.41 1.97 1.50 0.98 0.44 2.41 0.00
D16S416 63.2 0.68 0.60 0.49 0.35 0.19 0.68 0.00
D16S415 65.6 0.77 0.90 0.84 0.63 0.34 0.90 0.10
D16S3137 66.9 2.10 1.78 1.43 1.02 0.55 2.10 0.00
D16S3112 72.1 0.01 1.55 1.35 0.97 0.51 1.55 0.10
Note: LOD scores were calculated under an autosomal dominant mode of inheritance, a penetrance of 99.9% at variant recombination fractions.
Genetic coordinates in centimorgans according to The Genethon Human Genetic Linkage Map (http://www.genethon.fr/genethon.en.html) are in the
column ‘‘Location’’.
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frameshift mutation identified in this study locates in the
UCH conserved domain. UCH catalyzes the hydrolysis of
ubiquitin, resulting in deubiquitination and hence reduced
degradation of target proteins by the proteasome (D’Andrea
et al, 1998). Therefore, inactivation of the CYLD1 protein
may contribute to oncogenesis by enhancing the degrada-
tion of proteins that suppress cell proliferation or promote
apoptosis. This mutation occurs at the amino acid codon
785–786 of the CYLD1 protein and leads to the formation
of a premature termination codon 132 nucleotides down-
stream of the deletion site. Prediction of the potential
transmembrane segments of the mutant protein consists of
six transmembrane segments, indicating loss of the seventh
segment of the normal CYLD1 protein. It is possible that the
presence of 44 aberrant amino acids plays a role in the
pathogenesis of MFT, or the seventh segment of the normal
CYLD1 protein is critical in keeping from the tumorigenesis.
The CYLD1 gene may play a critical role in governing cell
fate decisions. Mutational changes in the CYLD1 gene
could affect the normal regulation of apocrine or eccrine
stem cell populations, which then give rise to the growth of
distinct tumor types because the physiologic function of the
encoded protein is disabled (Poblete Gutierrez et al, 2002).
In a further study, we will perform functional studies of this
frameshift mutation and further demonstrate the molecular
mechanism of MFT.
Materials and Methods
Subjects A three-generation family with MFT consisting of seven
affected and 12 unaffected individuals was identified through
proband from Anhui province in China (Fig 2). The diagnosis of
proband (Fig 5) was confirmed by typical clinical findings and
histopathological examinations obtained from three tumor speci-
mens. All family members received careful examinations by
experienced clinical dermatologists. The medical history of the
family members revealed neither cylindromas nor consistent
involvement of other systems. Clinical and histological character-
istics supported the diagnosis of MFT. After informed consent was
obtained, blood samples were collected from available family
members and 200 unrelated, unaffected control individuals.
Genomic DNAs were extracted from peripheral blood using the
Wizard Genomic DNA purification kit (Promega, Madison, WI). We
make the statement of institutional approvals and the statement of
adherence to Declaration of Helsinki Guidelines.
Genotyping We initially analyzed this family using polymorphic
microsatellite markers from chromosome 9p21. Linkage analysis
excluded the linkage to this region in this family. We then
genotyped this family with microsatellite markers spanning the
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Figure 2
Pedigree and haplotype analysis of the MFT family. The arrow indicates the proband; affected and unaffected individuals are respectively
represented by black and open symbols; disease-gene-bearing chromosomes are indicated with boxes; and blackened bars represent disease-
carrying haplotypes.
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locus for FC at 16q12–q13. Genethon linkage map (Dib et al, 1996)
was used to establish marker locations. The markers and their
location are shown in Table II. For the linkage study, genotypes
were obtained by polymerase chain reaction (PCR) with micro-
satellite markers of chromosomes 9p21 and 16q12–q13. The
reactions were performed with a touchdown program in a 5 mL
volume containing 10 mM Tris–HCl (PH 8.3), 50 mM KCl, 0.1 mg
per mL gelatin, 3.0 mM MgCl2, 0.2 mM of each dNTP, 0.04 mM of
each primer, 10 ng genomic DNA, and 0.2 U AmpliTaq Gold
(Applied Biosystems, Foster City, CA). The PCR conditions were as
follows: taq activation at 941C for 12 min, followed by 40 cycles,
each having denaturation at 941C for 30 s, annealing at 561C for
60 s and extension at 721C for 90 s, except that in the first 15 cycles
the annealing temperature decreased from 631C to 561C by 0.51C
per cycle, and the final extension was 721C for 10 min. The PCR
products were separated on a MegaBACE-1000 DNA sequencer
(Amersham BioScience, Piscataway, NJ). The size of the allele was
determined on the basis of MegaBACE ET400-R Size Standard.
Following the electrophoresis, data were collected and analyzed
with Intrument Control software version 2.1 and Genetic Profiler
software version 1.1. Genotypes of each locus were further
reviewed and scored independently by two observers and retyped
in case of discrepancy.
Linkage and haplotype analysis Two-point linkage analysis was
performed by Linkage programs version 5.10 (Lathrop and Lalouel,
1984). Autosomal dominant inheritance with 99.9% penetrance
was assumed. The affected allele frequency was taken as 0.00001
(Harada et al, 1996). Marker allele frequencies were evaluated
to be uniformly distributed. The recombination frequency was
assumed to be equal for both sexes. Haplotype was constructed
with Cyrillic version 2.02 software (Sobel and Lange, 1996).
Mutation detection of the CYLD1 gene The localization of the
CYLD1 gene within the critical region that we mapped on
chromosome 16q12–q13 encouraged us to search for mutations
in the CYLD1 gene. Amplification of all coding exons of the CYLD1
gene and the adjacent splice sites was carried out using PCR
primers designed by us shown in Table III.
Figure 4
All mutations in the CYLD1 gene. The mutation detected in this study is represented by a closed circle, and its location is indicated by a black
arrow pointing to exon 18. Each circle represents a specific mutation whose location is indicated by a yellow vertical line. Notes: , truncating
mutation responsible for MFT detected by us; ’, exon 18 of the CYLD1 gene; , truncating mutations responsible for FC; , splicing mutations
responsible for FC; , truncating mutations detected in an FC family co-occurring with MFT; |, splice site.
Figure 5
Clinical findings of the proband. Numerous small trichoepitheliomas
in the nasolabial folds.
Figure 3
Mutation analysis of exon 18 of the CYLD1 gene in the proband. Bidirectional automated sequence analysis of exon 18 of the CYLD1 gene
indicated a four-basepair deletion at the nucleotide position 5–8 in exon 18 of the CYLD1 gene, designated as c.2355–2358delCAGA.
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PCR was carried out in a 25 mL total volume, containing 20 ng
genomic DNA, 10 mM Tris–HCl (pH 8.3), 50 mM KCl, 3.0 mM
MgCl2, 0.01% gelatine, 0.2 mM dNTPs, 10 pmol of each primer,
and 0.75 U HotStarsTaq (QIAgene, Germany). The PCR conditions
were: HotStarsTaq activation at 951C for 15 min, followed by 40
cycles, each having denaturation at 941C for 40 s, annealing at
581C for 40 s and extension at 721C for 40 s, except that in the first
10 cycles the annealing temperature decreased from 631C to 581C
by 0.51C per cycle, and the final extension was 721C for 10 min.
PCR products were directly sequenced on an ABI 377 DNA
sequencer (Perkin-Elmer).
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Appendix: Electronic Database Information
Accession numbers and URLs for data in this paper are as
follows:
 Accession numbers: OMIM: MFT, 601606; FC, #132700;
CYLD1, 605018; Genebank: CYLD1, AJ250014; cDNA
of CYLD1: NM_015247.
 Genethon: http://www.genethon.fr/genethon.en.html;
 GenBank: http://www.ncbi.nlm.nih.gov/web/search/
index.html;
 Online Mendelian Inheritance in Man (OMIM): http://
www.ncbi.nlm.nih.bov/OMIM;
 Expert Protein Analysis System (ExPASy): http://www.
expasy.ch.
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